Logo image of PODD

INSULET CORP (PODD) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:PODD - US45784P1012 - Common Stock

284.24 USD
-2.79 (-0.97%)
Last: 12/31/2025, 8:24:16 PM
284.24 USD
0 (0%)
After Hours: 12/31/2025, 8:24:16 PM

PODD Key Statistics, Chart & Performance

Key Statistics
Market Cap20.00B
Revenue(TTM)2.52B
Net Income(TTM)246.20M
Shares70.35M
Float70.13M
52 Week High354.88
52 Week Low230.05
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)4.57
PE62.2
Fwd PE44.78
Earnings (Next)02-18 2026-02-18/amc
IPO2007-05-15
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


PODD short term performance overview.The bars show the price performance of PODD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -2 -4 -6 -8

PODD long term performance overview.The bars show the price performance of PODD in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 20 30

The current stock price of PODD is 284.24 USD. In the past month the price decreased by -8.01%. In the past year, price increased by 6.74%.

INSULET CORP / PODD Daily stock chart

PODD Latest News, Press Relases and Analysis

PODD Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 25.11 217.86B
ISRG INTUITIVE SURGICAL INC 65.78 200.77B
BSX BOSTON SCIENTIFIC CORP 32.32 141.35B
SYK STRYKER CORP 26.69 134.41B
BDX BECTON DICKINSON AND CO 13.46 55.39B
IDXX IDEXX LABORATORIES INC 53.65 54.02B
EW EDWARDS LIFESCIENCES CORP 33.17 49.47B
GEHC GE HEALTHCARE TECHNOLOGY 17.87 37.36B
RMD RESMED INC 24.33 35.16B
DXCM DEXCOM INC 35.68 25.89B
ZBH ZIMMER BIOMET HOLDINGS INC 11.11 17.82B
HOLX HOLOGIC INC 17.44 16.60B

About PODD

Company Profile

PODD logo image Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 3,900 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

Company Info

INSULET CORP

100 Nagog Park

Acton MASSACHUSETTS 01720 US

CEO: Shacey Petrovic

Employees: 3900

PODD Company Website

PODD Investor Relations

Phone: 19786007000

INSULET CORP / PODD FAQ

Can you describe the business of INSULET CORP?

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 3,900 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.


What is the current price of PODD stock?

The current stock price of PODD is 284.24 USD. The price decreased by -0.97% in the last trading session.


Does INSULET CORP pay dividends?

PODD does not pay a dividend.


How is the ChartMill rating for INSULET CORP?

PODD has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


What sector and industry does INSULET CORP belong to?

INSULET CORP (PODD) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


Can you provide the ownership details for PODD stock?

You can find the ownership structure of INSULET CORP (PODD) on the Ownership tab.


PODD Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to PODD. When comparing the yearly performance of all stocks, PODD turns out to be only a medium performer in the overall market: it outperformed 40.22% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PODD Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to PODD. PODD has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PODD Financial Highlights

Over the last trailing twelve months PODD reported a non-GAAP Earnings per Share(EPS) of 4.57. The EPS increased by 27.65% compared to the year before.


Industry RankSector Rank
PM (TTM) 9.76%
ROA 8.13%
ROE 17.79%
Debt/Equity 0.68
Chartmill High Growth Momentum
EPS Q2Q%37.78%
Sales Q2Q%29.86%
EPS 1Y (TTM)27.65%
Revenue 1Y (TTM)27.12%

PODD Forecast & Estimates

33 analysts have analysed PODD and the average price target is 385.28 USD. This implies a price increase of 35.55% is expected in the next year compared to the current price of 284.24.

For the next year, analysts expect an EPS growth of 49.49% and a revenue growth 30.95% for PODD


Analysts
Analysts86.06
Price Target385.28 (35.55%)
EPS Next Y49.49%
Revenue Next Year30.95%

PODD Ownership

Ownership
Inst Owners100.99%
Ins Owners0.29%
Short Float %2.97%
Short Ratio3.06